drugset / Trial / NCT03244020
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Phase 4
Enrolling by invitation
2868 enrolled
Massachusetts General Hospital
Johns Hopkins University · collabUniversity of Missouri-Columbia · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.
Timeline
- Start
- 2018-02-16
- Primary completion
- 2027-12-31
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 325 mg | Oral |
| Subject | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |